Evidence map›Paper›PMID 36698209›Full record

ArticleMolecular brain2023

Aβ42 treatment of the brain side reduced the level of flotillin from endothelial cells on the blood side via FGF-2 signaling in a blood-brain barrier model.

Tomohisa Nakamura, Tadahiro Hashita, Yuxin Chen, Yuan Gao, Yang Sun, Sadequl Islam, Hiroyuki Sato, Yasuyuki Shibuya, Kun Zou, Tamihide Matsunaga and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular brain, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Tomohisa Nakamura *Department of Biochemistry, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-Cyo, Mizuho-Ku, Nagoya, 467-8601, Japan.
Tadahiro Hashita *Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-Ku, Nagoya, 467-8603, Japan.
Yuxin ChenDepartment of Biochemistry, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-Cyo, Mizuho-Ku, Nagoya, 467-8601, Japan.
Yuan GaoDepartment of Biochemistry, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-Cyo, Mizuho-Ku, Nagoya, 467-8601, Japan.
Yang SunDepartment of Biochemistry, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-Cyo, Mizuho-Ku, Nagoya, 467-8601, Japan.
Sadequl IslamDepartment of Biochemistry, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-Cyo, Mizuho-Ku, Nagoya, 467-8601, Japan.
Hiroyuki SatoDepartment of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-Ku, Nagoya, 467-8603, Japan.
Yasuyuki ShibuyaDepartment of Maxillofacial Surgery, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-Cyo, Mizuho-Ku, Nagoya, 467-8601, Japan.
Kun ZouDepartment of Biochemistry, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-Cyo, Mizuho-Ku, Nagoya, 467-8601, Japan.
Tamihide MatsunagaDepartment of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-Ku, Nagoya, 467-8603, Japan.
Makoto MichikawaDepartment of Biochemistry, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-Cyo, Mizuho-Ku, Nagoya, 467-8601, Japan. michi@med.nagoya-cu.ac.jp.ORCID 0000-0001-5397-2709
Nagoya City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our previous study showed that the flotillin level is decreased in the blood of patients with Alzheimer's disease (AD) when compared to that of patients with non-AD and vascular dementia; however, the molecular mechanism remains to be determined. In this study, to elucidate whether Aβ accumulation in the brain has an effect on the blood flotillin level, we used our previously established blood-brain barrier (BBB) culture model using microvascular endothelial cells obtained from human induced pluripotent stem cells (iBMECs) and astrocytes prepared from rat cortex. In this BBB model with iBMECs plated on the upper compartment (blood side) and astrocytes plated on the lower compartment (brain side), the trans-endothelial electrical resistance values are high (over 1500 Ωm

Indexed as

Alzheimer DiseaseInduced Pluripotent Stem CellsAmyloid beta-PeptidesAnimalsBlood-Brain BarrierBrainEndothelial CellsFibroblast Growth Factor 2HumansMembrane ProteinsPeptide FragmentsRatsAmyloid beta-Peptidesamyloid beta-protein (1-42)Fibroblast Growth Factor 2flotillinsMembrane ProteinsPeptide FragmentsAlzheimer’s diseaseAmyloid β-proteinBlood flotillinMicrovascular endothelial cells

Identifiers

PMID36698209
PMCPMC9878866
OpenAlexW4318046754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.